Subject
Pharmacology (medical),Biological Psychiatry,Psychiatry and Mental health,Neurology (clinical),Neurology,Pharmacology
Reference97 articles.
1. Administration, F.a.D., 2006. FDA approves Emsam (selegiline) as first drug patch for depression [online].
2. Selegiline in the treatment of attention deficit hyperactivity disorder in children: a double blind and randomized trial;Akhondzadeh;Prog. Neuropsychopharmacol. Biol. Psychiatry,2003
3. Efficacy of selegiline add on therapy to risperidone in the treatment of the negative symptoms of schizophrenia: a double-blind randomized placebo-controlled study;Amiri;Hum. Psychopharmacol.,2008
4. A double-blind, placebo-controlled trial of the safety and efficacy of selegiline transdermal system without dietary restrictions in patients with major depressive disorder;Amsterdam;J. Clin. Psychiatry,2003
5. Selegiline transdermal system in the prevention of relapse of major depressive disorder: a 52-week, double-blind, placebo-substitution, parallel-group clinical trial;Amsterdam;J. Clin. Psychopharmacol.,2006
Cited by
3 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献